|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC35C1 |
Gene summary for SLC35C1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC35C1 | Gene ID | 55343 |
| Gene name | solute carrier family 35 member C1 | |
| Gene Alias | CDG2C | |
| Cytomap | 11p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q96A29 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55343 | SLC35C1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.11e-03 | 9.90e-02 | 0.0155 |
| 55343 | SLC35C1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 8.42e-13 | 5.18e-01 | -0.1808 |
| 55343 | SLC35C1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.74e-10 | 3.32e-01 | -0.0811 |
| 55343 | SLC35C1 | HTA11_78_2000001011 | Human | Colorectum | AD | 6.83e-11 | 2.28e-01 | -0.1088 |
| 55343 | SLC35C1 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.36e-13 | 3.42e-01 | -0.1954 |
| 55343 | SLC35C1 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.84e-05 | 6.69e-01 | -0.2602 |
| 55343 | SLC35C1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 6.04e-08 | 7.69e-01 | -0.2196 |
| 55343 | SLC35C1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 6.24e-09 | 2.39e-01 | -0.1207 |
| 55343 | SLC35C1 | HTA11_83_2000001011 | Human | Colorectum | SER | 5.84e-08 | 3.58e-01 | -0.1526 |
| 55343 | SLC35C1 | HTA11_696_2000001011 | Human | Colorectum | AD | 9.84e-12 | 3.42e-01 | -0.1464 |
| 55343 | SLC35C1 | HTA11_866_2000001011 | Human | Colorectum | AD | 7.55e-08 | 1.75e-01 | -0.1001 |
| 55343 | SLC35C1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.01e-11 | 4.49e-01 | -0.059 |
| 55343 | SLC35C1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 3.37e-04 | 3.94e-01 | -0.1706 |
| 55343 | SLC35C1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.83e-03 | 3.13e-01 | -0.2061 |
| 55343 | SLC35C1 | HTA11_866_3004761011 | Human | Colorectum | AD | 5.04e-04 | 1.73e-01 | 0.096 |
| 55343 | SLC35C1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 9.20e-04 | 2.97e-01 | 0.0528 |
| 55343 | SLC35C1 | HTA11_7663_2000001011 | Human | Colorectum | SER | 2.53e-03 | 2.85e-01 | 0.0131 |
| 55343 | SLC35C1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.35e-07 | 2.19e-01 | 0.0674 |
| 55343 | SLC35C1 | HTA11_7469_2000001011 | Human | Colorectum | AD | 6.95e-03 | 4.43e-01 | -0.0124 |
| 55343 | SLC35C1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.26e-05 | 2.27e-01 | 0.0588 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0015931 | Colorectum | AD | nucleobase-containing compound transport | 73/3918 | 222/18723 | 2.02e-05 | 4.10e-04 | 73 |
| GO:0030258 | Colorectum | AD | lipid modification | 67/3918 | 212/18723 | 1.66e-04 | 2.27e-03 | 67 |
| GO:0006486 | Colorectum | AD | protein glycosylation | 64/3918 | 226/18723 | 4.86e-03 | 3.27e-02 | 64 |
| GO:0043413 | Colorectum | AD | macromolecule glycosylation | 64/3918 | 226/18723 | 4.86e-03 | 3.27e-02 | 64 |
| GO:0070085 | Colorectum | AD | glycosylation | 67/3918 | 240/18723 | 5.78e-03 | 3.67e-02 | 67 |
| GO:0007219 | Colorectum | AD | Notch signaling pathway | 50/3918 | 172/18723 | 6.92e-03 | 4.26e-02 | 50 |
| GO:00159311 | Colorectum | SER | nucleobase-containing compound transport | 54/2897 | 222/18723 | 3.65e-04 | 5.67e-03 | 54 |
| GO:00302581 | Colorectum | SER | lipid modification | 47/2897 | 212/18723 | 6.01e-03 | 4.38e-02 | 47 |
| GO:00159312 | Colorectum | MSS | nucleobase-containing compound transport | 70/3467 | 222/18723 | 1.92e-06 | 6.01e-05 | 70 |
| GO:00302582 | Colorectum | MSS | lipid modification | 57/3467 | 212/18723 | 1.64e-03 | 1.49e-02 | 57 |
| GO:001593117 | Esophagus | ESCC | nucleobase-containing compound transport | 162/8552 | 222/18723 | 9.87e-17 | 7.93e-15 | 162 |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
| GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00072197 | Esophagus | ESCC | Notch signaling pathway | 106/8552 | 172/18723 | 1.74e-05 | 1.55e-04 | 106 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:0045746 | Esophagus | ESCC | negative regulation of Notch signaling pathway | 28/8552 | 36/18723 | 8.62e-05 | 6.22e-04 | 28 |
| GO:00085935 | Esophagus | ESCC | regulation of Notch signaling pathway | 59/8552 | 95/18723 | 9.12e-04 | 4.65e-03 | 59 |
| GO:00302586 | Esophagus | ESCC | lipid modification | 116/8552 | 212/18723 | 4.90e-03 | 1.89e-02 | 116 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC35C1 | SNV | Missense_Mutation | c.546N>T | p.Trp182Cys | p.W182C | Q96A29 | protein_coding | tolerated(0.06) | benign(0.022) | TCGA-B6-A0RS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| SLC35C1 | SNV | Missense_Mutation | c.716N>A | p.Cys239Tyr | p.C239Y | Q96A29 | protein_coding | deleterious(0.01) | possibly_damaging(0.871) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| SLC35C1 | SNV | Missense_Mutation | novel | c.400T>A | p.Cys134Ser | p.C134S | Q96A29 | protein_coding | tolerated(0.05) | possibly_damaging(0.677) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
| SLC35C1 | SNV | Missense_Mutation | novel | c.665N>T | p.Ala222Val | p.A222V | Q96A29 | protein_coding | tolerated(0.53) | benign(0.014) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SLC35C1 | SNV | Missense_Mutation | c.1077G>C | p.Lys359Asn | p.K359N | Q96A29 | protein_coding | tolerated(0.06) | benign(0.061) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| SLC35C1 | SNV | Missense_Mutation | c.194N>A | p.Ser65Asn | p.S65N | Q96A29 | protein_coding | tolerated(0.19) | benign(0.013) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SLC35C1 | SNV | Missense_Mutation | novel | c.32T>G | p.Ile11Ser | p.I11S | Q96A29 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.796) | TCGA-AA-A02W-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| SLC35C1 | SNV | Missense_Mutation | rs753103441 | c.974N>T | p.Thr325Met | p.T325M | Q96A29 | protein_coding | tolerated(0.28) | benign(0.108) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SLC35C1 | SNV | Missense_Mutation | rs374599500 | c.766N>T | p.Arg256Cys | p.R256C | Q96A29 | protein_coding | tolerated(0.16) | benign(0.098) | TCGA-A5-A0VQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| SLC35C1 | SNV | Missense_Mutation | c.250A>G | p.Thr84Ala | p.T84A | Q96A29 | protein_coding | tolerated(0.15) | benign(0.085) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |